
There is no available clinical evidence to support the combined use of bosutinib and nemolizumab for concurrent conditions.
clinical evidence, nemolizumab, treatment, concurrent conditions, oncology, bosutinib, pharmacology, long-term management, patients, combination therapy
clinical evidence, nemolizumab, treatment, concurrent conditions, oncology, bosutinib, pharmacology, long-term management, patients, combination therapy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
